Sphera Funds Management LTD. Has $2.55 Million Stock Holdings in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

Sphera Funds Management LTD. decreased its stake in shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) by 8.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,502,429 shares of the company's stock after selling 145,175 shares during the period. Sphera Funds Management LTD. owned 3.68% of Vigil Neuroscience worth $2,554,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC raised its position in shares of Vigil Neuroscience by 53.0% in the 4th quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company's stock worth $41,000 after buying an additional 8,358 shares during the period. Jane Street Group LLC acquired a new stake in shares of Vigil Neuroscience during the 4th quarter worth approximately $83,000. Barclays PLC lifted its position in shares of Vigil Neuroscience by 43.6% during the 4th quarter. Barclays PLC now owns 64,049 shares of the company's stock valued at $109,000 after acquiring an additional 19,436 shares during the last quarter. Northern Trust Corp raised its position in shares of Vigil Neuroscience by 29.0% during the fourth quarter. Northern Trust Corp now owns 64,737 shares of the company's stock worth $110,000 after purchasing an additional 14,572 shares during the period. Finally, Boothbay Fund Management LLC purchased a new position in shares of Vigil Neuroscience in the fourth quarter worth approximately $249,000. Institutional investors and hedge funds own 83.64% of the company's stock.

Vigil Neuroscience Trading Down 4.8%

Shares of Vigil Neuroscience stock traded down $0.12 on Wednesday, reaching $2.36. 19,675 shares of the company were exchanged, compared to its average volume of 476,171. The company has a market capitalization of $110.15 million, a price-to-earnings ratio of -1.15 and a beta of 1.90. Vigil Neuroscience, Inc. has a one year low of $1.31 and a one year high of $6.06. The company has a 50-day moving average of $1.95 and a 200 day moving average of $2.24.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.04. Analysts predict that Vigil Neuroscience, Inc. will post -2.07 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have commented on VIGL. HC Wainwright decreased their price objective on Vigil Neuroscience from $17.00 to $14.00 and set a "buy" rating for the company in a research report on Friday, March 14th. Guggenheim restated a "buy" rating on shares of Vigil Neuroscience in a research note on Friday, January 24th. William Blair upgraded Vigil Neuroscience to a "strong-buy" rating in a report on Thursday, April 24th. Finally, Wedbush reiterated an "outperform" rating and issued a $13.00 target price on shares of Vigil Neuroscience in a research note on Monday, May 5th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $16.25.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.